Published Studies Related to Macugen (Pegaptanib)
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. 
(CRVO)... CONCLUSIONS: Based on this 30-week study, intravitreous pegaptanib sodium appears
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in
patients with neovascular age-related macular degeneration. 
degeneration (AMD)... CONCLUSIONS: At doses up to 10-fold higher than the 0.3-mg dose approved for the
Pegaptanib: a novel approach to ocular neovascularization. 
CONCLUSIONS: Pegaptanib, a new inhibitor of ocular neovascularization, provides
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib
for neovascular age-related macular degeneration. 
in patients with neovascular age-related macular degeneration (AMD)... CONCLUSIONS: Continuing visual benefit was observed in patients who were
Enhanced efficacy associated with early treatment of neovascular age-related
macular degeneration with pegaptanib sodium: an exploratory analysis. 
pegaptanib sodium... CONCLUSION: Early detection and treatment with pegaptanib may result in superior
Clinical Trials Related to Macugen (Pegaptanib)
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) [Completed]
Patients with proliferative diabetic retinopathy or clinically significant diabetic macular
edema requiring surgical intervention will receive a pre-operative injection of Macugen. An
initial, pre-injection vitreous tap will be done in order to provide baseline VRGF 165 and
cytokine levels. At the onset of the vitrectomy, a second vitreous sample will be taken to
obtain intra-operative levels of Macugen, VEGF 165 and cytokines.
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion [Completed]
The purpose of this study is to evaluate the effect of intravitreal injections of Macugen
every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion
(BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that
chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.
Intravitreal Macugen for Ischaemic Diabetic Macular Oedema [Completed]
Diabetic macular oedema (DME) is one of the leading causes of blindness in the United
Kingdom's working population. It affects the macula, which lies at the centre of the retina,
at the back of the eye. Damage to the macula can occur either because the blood supply is
reduced (ischaemic DME), or because the blood vessels are leaking excessively (exudative
A chemical called vascular endothelial growth factor (VEGF) may underlie some of the
abnormalities seen in DME. Studies have shown that VEGF encourages leakage of fluid from
blood vessels and increases the stickiness of white blood cells. When white blood cells are
sticky they can attach to blood vessel walls. This may cause small blood vessels to block,
and lead to ischaemia.
Laser treatment often helps to stabilise exudative DME, but there is currently no recognised
treatment for ischaemic DME. Macugen (pegaptanib), a drug that inactivates VEGF, has been
tried and found to be of benefit in treating exudative DME. Since VEGF promotes ischaemia,
it is possible that Macugen will also prove to be beneficial for ischaemic DME. This has not
been tested before.
A healthy macula is essential for good vision. The innermost area of the macula, the foveal
avascular zone (FAZ), is the most important part. The FAZ is enlarged when it is ischaemic.
This is a pilot study to assess whether Macugen can reduce the size of the FAZ in ischaemic
DME. The investigators will also assess whether it can reduce retinal thickness and improve
vision in ischaemic DME. Thirty patients will be involved in the study for thirty weeks
each. They will have their eyes examined and receive an injection of Macugen into the eye
every 6 weeks. The study is taking place in the Oxford Eye Hospital and is being funded by
Pfizer, the company that makes Macugen.
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. [Completed]
To assess effectiveness of Macugen for treatment of neovascular age-related macular
degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of
administration and combination with other treatments will also be evaluated.
The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema [Terminated]
This research is being done to look at the effects of an experimental drug called pegaptanib
(also called Macugen) for the treatment of swelling in the retina (the light sensitive
tissue in the back of the eye) that can occur after cataract surgery. Swelling in the retina
can lead to blurry vision.
The only treatment available for this condition is eye drops that decrease swelling in the
back of the eye, but eye drops may not decrease the swelling in everyone. We want to see if
pegaptanib can decrease swelling in the retina and improve vision in patients with swelling
after cataract surgery.
Reports of Suspected Macugen (Pegaptanib) Side Effects
Visual Acuity Reduced (6),
Cerebral Infarction (4),
Intraocular Pressure Increased (3),
Retinal Haemorrhage (3),
Drug Ineffective (2),
Upper Limb Fracture (2),
Aphasia (2), more >>